Startups
Could Denmark become the site of Europe’s answer to Silicon Valley? The Danish government is banking on it. If it comes to fruition, the project could provide up to 12,000 life science jobs.
Seattle-based Neoleukin Therapeutics spun out of the University of Washington Medicine’s Institute for Protein Design’s research with the help of CoMotion, a collaborative innovation hub.
The JP Morgan Healthcare Conference is wrapping up today and as usual, it’s host to some of the biggest names in biopharma, but it’s also a venue where tiny biotechs and even mid-size biopharma companies go to meet-and-greet with others in the industry.
As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. Let us know which topics you want to hear more about.
Biotech entrepreneur Vivek Ramaswamy has launched another subsidiary for Roivant Sciences. Ramaswamy will provide an update on the new company, as well as other members of the Roivant family during a Monday presentation at JPM19.
On opposite sides of the country, the two new companies tackle different methods to treat disease.
New biotech Tiburio has surged onto the scene with $31 million in financing and two novel Phase II-ready assets licensed from Ipsen Pharma. The new company, spun out of orphan drug accelerator Cydan is focused on rare endocrine diseases.
EnClear aims to develop a device that will continuously clear toxic proteins from cerebrospinal fluids.
Most of the IPOs that occurred in the Bay State have been well-documented by BioSpace. But, with a new calendar year upon us, it’s a good idea to look back at a banner year of capitalization that may not repeat when January rolls around. With the turn of the year only days away, BioSpace takes a look at some of the key Massachusetts-based IPOs.
Under the terms of the agreement, Pfizer will combine its consumer healthcare business with GSK’s existing consumer healthcare business. The combined global sales were about $12.7 billion last year. Closing is expected in the second half of 2019, dependent on GSK’s shareholder approval and regulatory approvals.
PRESS RELEASES